AR071831A1 - Sistemas no invasivos y metodos para fotobiomodulacion in situ. composicion farmaceutica. kit. - Google Patents
Sistemas no invasivos y metodos para fotobiomodulacion in situ. composicion farmaceutica. kit.Info
- Publication number
- AR071831A1 AR071831A1 ARP090101189A ARP090101189A AR071831A1 AR 071831 A1 AR071831 A1 AR 071831A1 AR P090101189 A ARP090101189 A AR P090101189A AR P090101189 A ARP090101189 A AR P090101189A AR 071831 A1 AR071831 A1 AR 071831A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- energy
- activation
- agent
- active
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 9
- 230000004913 activation Effects 0.000 abstract 7
- 230000004071 biological effect Effects 0.000 abstract 4
- 230000000977 initiatory effect Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229940027041 8-mop Drugs 0.000 abstract 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960003569 hematoporphyrin Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A61N5/022—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0642—Irradiating part of the body at a certain distance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Developmental Disabilities (AREA)
Abstract
Productos, composiciones, sistemas y metodos para modificar una estructura blanco que media o est asociada con una actividad biologica, incluyendo tratamiento de afecciones, trastornos, o enfermedades mediadas por o asociadas con una estructura blanco, tal como un virus, una celula, estructura celular o estructura extracelular. Kits que contienen los productos o las composiciones formuladas o configuradas y sistemas para usar en la puesta en pr ctica de estos metodos. Reivindicacion 1: Una composicion farmaceutica para modificar una estructura pretendida que media o est asociada con una actividad biologica, que comprende: por lo menos un agente seleccionado del grupo que consiste en agentes de modulacion de energ¡a, agentes activosplasmonicos y combinaciones de los anteriores; y a veh¡culo aceptable desde el punto de vista farmaceutico. Reivindicacion 2: La composicion farmaceutica de la reivindicacion 1, comprende adem s una fuente de energ¡a qu¡mica. Reivindicacion 3: La composicion farmaceutica de la reivindicacion 2, en la cual la fuente de energ¡a qu¡mica es un elemento seleccionado del grupo que consiste en compuestos fluorescentes, compuestos quimioluminiscentes, compuestos bioluminiscentes y enzimas emisoras de luz. Reivindicacion 5: La composicion farmaceutica de la reivindicacion 1, que comprende adem s por lo menos un agente farmaceutico susceptible de activacion. Reivindicacion 9: La composicion farmaceutica de la reivindicacion 5, en la cual el por lo menos un agente farmaceutico susceptible de activacion es 8-MOP o AMT. Reivindicacion 10: La composicion farmaceutica de la reivindicacion 5, en la cual el por lo menos un agente farmaceutico susceptible de activacion es uno seleccionado de 7,8-dimetil-1 0-ribitilo, isoaloxazina, 7,8,10-trimetilisoaloxazina, 7,8-dimetilaloxazina, isoaloxazina-adenina dinucleotido, aloxazina mononucleotido, tetrasulfonato de aluminio (III) ftalocianina, hematoporfirina, y ftadocianina. Reivindicacion 12: La composicion farmaceutica de la reivindicacion 11, en la cual el veh¡culo es uno seleccionado de insulina, interleucina, timopoyetina o transferrina. Reivindicacion 31: La composicion farmaceutica de la reivindicacion 28, en la cual el agente activo-plasmonico es una sonda PEPST que comprende nano estructuras de metal activas con plasmonicos. Reivindicacion 61: La composicion farmaceutica de la reivindicacion 1, comprende adem s por lo menos un aditivo que tiene un efecto terapeutico o de diagnostico complementario, en la cual dicho aditivo es por lo menos un elemento seleccionado del grupo que consiste en antioxidantes, adyuvantes, fuentes de energ¡a qu¡micas, y combinaciones de los anteriores. Reivindicacion 105: Una composicion que comprende por lo menos un agente farmaceutico susceptible de activacion (PA) que es capaz de efectuar un cambio predeterminado en una estructura pretendida cuando se activa, y, en forma opcional, por lo menos un elemento seleccionado del grupo que consiste en agentes de modulacion de energ¡a, agentes activos-plasmonicos y combinaciones de los anteriores, para usar en la fabricacion de un medicamento para un tratamiento que modifica una estructura pretendida que media o est asociada con una actividad biologica, en el cual el tratamiento comprende: (1) contactar dicha estructura pretendida con la composicion farmaceutica; y (2) aplicar una energ¡a de iniciacion proveniente de una fuente de energ¡a de iniciacion a dicha estructura pretendida, donde el agente de modulacion de energ¡a, si est presente, eleva o disminuye la energ¡a de iniciacion a una energ¡a de activacion capaz de activar el por lo menos un agente farmaceutico susceptible de activacion; donde el agente activo-plasmonico, si est presente, potencia o modifica la energ¡a de iniciacion aplicada o la energ¡a de activacion generada por el agente de modulacion de energ¡a, o ambos; y de este modo logrando que ocurra el cambio predeterminado a la estructura pretendida, en el cual dicho cambio predeterminado modifica la estructura pretendida y modula la actividad biologica de la estructura pretendida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4256108P | 2008-04-04 | 2008-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071831A1 true AR071831A1 (es) | 2010-07-21 |
Family
ID=41135939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101189A AR071831A1 (es) | 2008-04-04 | 2009-04-03 | Sistemas no invasivos y metodos para fotobiomodulacion in situ. composicion farmaceutica. kit. |
Country Status (10)
Country | Link |
---|---|
US (4) | US20100016783A1 (es) |
EP (2) | EP3300744A1 (es) |
JP (5) | JP5967935B2 (es) |
CN (3) | CN105288619A (es) |
AR (1) | AR071831A1 (es) |
CA (3) | CA2720513C (es) |
CL (1) | CL2009000816A1 (es) |
SA (1) | SA109300207B1 (es) |
TW (3) | TWI615170B (es) |
WO (1) | WO2009124189A1 (es) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130274837A1 (en) * | 1998-10-23 | 2013-10-17 | Babak Nemati | Systems and Methods to Enhance Optical Transparency of Biological Tissues for Photobiomodulation |
US7520860B2 (en) * | 2005-04-13 | 2009-04-21 | Marie G. Johnson | Detection of coronary artery disease using an electronic stethoscope |
US20080269730A1 (en) | 2005-04-14 | 2008-10-30 | Dotson Robert S | Ophthalmic Phototherapy Device and Associated Treatment Method |
US20130079759A1 (en) | 2005-04-14 | 2013-03-28 | Robert S. Dotson | Ophthalmic Phototherapy Device and Associated Treatment Method |
US9238150B2 (en) * | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
JP2009502140A (ja) * | 2005-07-22 | 2009-01-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 光活性化陽イオンチャネルおよびその使用 |
US10052497B2 (en) * | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US8262713B2 (en) * | 2005-09-26 | 2012-09-11 | Depuy Spine, Inc. | Red light implant for treating osteoporosis |
US8398692B2 (en) | 2007-01-10 | 2013-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
WO2008101128A1 (en) | 2007-02-14 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
US9488916B2 (en) | 2007-04-08 | 2016-11-08 | Immunolight, Llc. | Interior energy-activation of photo-reactive species inside a medium or body |
US9358292B2 (en) * | 2007-04-08 | 2016-06-07 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders |
US10596387B2 (en) | 2007-04-08 | 2020-03-24 | Immunolight, Llc. | Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties |
US10441810B2 (en) | 2007-04-08 | 2019-10-15 | Immunolight, Llc | X-ray psoralen activated cancer therapy (X-PACT) |
WO2012164393A1 (en) * | 2011-05-31 | 2012-12-06 | Clarencew Pty.Ltd | Methods for preventing and treating motor-related neurological conditions |
WO2015143065A1 (en) * | 2014-03-18 | 2015-09-24 | Immunolight, Llc | Improved adhesive bonding composition and method of use |
US10035027B2 (en) * | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
US20110022129A1 (en) * | 2007-11-05 | 2011-01-27 | Prud Homme Robert K | Nanoparticles for photodynamic therapy |
US9302116B2 (en) | 2007-11-06 | 2016-04-05 | Duke University | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation |
US8507785B2 (en) | 2007-11-06 | 2013-08-13 | Pacific Integrated Energy, Inc. | Photo induced enhanced field electron emission collector |
CL2009000560A1 (es) | 2008-03-11 | 2010-02-19 | Univ Duke | Un metodo para endurecer un medio endurecible por radiacion que comprende colocar una composicion dentro de un objeto para ser endurecido, la aplicacion de al menos uno elegido entre rayos x, rayos gama o haz de electrones a traves del objeto y dentro de la composicion. |
US20100004623A1 (en) * | 2008-03-27 | 2010-01-07 | Angiodynamics, Inc. | Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation |
ES2608498T3 (es) | 2008-04-23 | 2017-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sistemas, métodos y composiciones para la estimulación óptica de células diana |
EP2910637A1 (en) | 2008-05-20 | 2015-08-26 | University of Florida Research Foundation, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
CN102076866A (zh) | 2008-05-29 | 2011-05-25 | 利兰·斯坦福青年大学托管委员会 | 光学控制第二信使的细胞系、系统和方法 |
ES2612052T3 (es) | 2008-06-17 | 2017-05-11 | The Board Of Trustees Of The Leland Stanford Junior University | Dispositivos para la estimulación óptica de células diana, utilizando un elemento de transmisión óptica |
WO2009155369A1 (en) * | 2008-06-17 | 2009-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
WO2010006049A1 (en) | 2008-07-08 | 2010-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
US8770203B2 (en) | 2008-07-14 | 2014-07-08 | Immunolight, Llc. | Advanced methods and systems for treating cell proliferation disorders |
KR101028949B1 (ko) * | 2008-07-23 | 2011-04-12 | 재단법인서울대학교산학협력재단 | 신경 유저 인터페이스 장치, 방법 및 뇌 활동 측정 장치 |
NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
US9149647B2 (en) * | 2008-12-14 | 2015-10-06 | C Laser, Inc. | Method for deep tissue laser treatments using low intensity laser therapy causing selective destruction of Nociceptive nerves |
US9693825B2 (en) | 2008-12-14 | 2017-07-04 | C Laser, Inc. | Fiber embedded hollow needle for percutaneous delivery of laser energy |
WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
WO2011071989A2 (en) * | 2009-12-08 | 2011-06-16 | Aum Cardiovascular, Llc | Systems and methods for detecting cardiovascular disease |
US20110166560A1 (en) * | 2010-01-07 | 2011-07-07 | Solar System Beauty Corporation | Skin care laser device |
US9265576B2 (en) * | 2010-02-21 | 2016-02-23 | C Laser, Inc. | Laser generator for medical treatment |
US10206742B2 (en) | 2010-02-21 | 2019-02-19 | C Laser, Inc. | Fiber embedded hollow spikes for percutaneous delivery of laser energy |
EP2547762B1 (en) | 2010-03-17 | 2018-04-25 | The Board of Trustees of the Leland Stanford Junior University | Light-sensitive ion-passing molecules |
WO2011127088A2 (en) | 2010-04-05 | 2011-10-13 | Eos Neuroscience, Inc. | Methods and compositions for decreasing chronic pain |
US9348078B2 (en) | 2010-06-08 | 2016-05-24 | Pacific Integrated Energy, Inc. | Optical antennas with enhanced fields and electron emission |
WO2011163646A2 (en) * | 2010-06-25 | 2011-12-29 | Marek Malecki | Methods for detection, diagnosis and selective eradication of neoplasms and circulating tumor cells using multidomain biotags |
US8192429B2 (en) | 2010-06-29 | 2012-06-05 | Theravant, Inc. | Abnormality eradication through resonance |
US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
EP2608762B2 (en) | 2010-08-27 | 2020-05-13 | Sienna Biopharmaceuticals, Inc. | Compositions and methods for targeted thermomodulation |
FR2964663B1 (fr) * | 2010-09-14 | 2013-10-11 | Oreal | Composition cosmetique comprenant une matiere colorante, ladite matiere colorante et procede de traitement cosmetique |
US9700368B2 (en) | 2010-10-13 | 2017-07-11 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
CN103298480B (zh) | 2010-11-05 | 2016-10-12 | 斯坦福大学托管董事会 | 记忆功能的控制和表征 |
AU2011323226B2 (en) | 2010-11-05 | 2015-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
ES2684307T3 (es) | 2010-11-05 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Proteínas estabilizadas de tipo opsina de función escalonada y métodos de uso de las mismas |
CN110215614A (zh) | 2010-11-05 | 2019-09-10 | 斯坦福大学托管董事会 | 用于光遗传学方法的光的上转换 |
AU2011323237B2 (en) | 2010-11-05 | 2015-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-controlled CNS dysfunction |
CN103476456B (zh) | 2010-11-05 | 2017-10-03 | 斯坦福大学托管董事会 | 奖赏相关行为的光遗传学控制 |
US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
WO2012092057A1 (en) * | 2010-12-29 | 2012-07-05 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue with light |
CZ303355B6 (cs) * | 2011-01-06 | 2012-08-08 | Centrum organické chemie s.r.o. | Zpusob inaktivace patogenních prionu, fotosenzitizátor pro inaktivaci patogenních prionu a použití fotosenzitizátoru pro inaktivaci patogenních prionu |
US20120191148A1 (en) * | 2011-01-24 | 2012-07-26 | Actium BioSystems, LLC | System for correlating energy field characteristics with target particle characteristics in the application of an energy field to a living organism for treatment of invasive agents |
US8757166B2 (en) | 2011-01-24 | 2014-06-24 | Actium BioSystems, LLC | System for defining energy field characteristics to illuminate nano-particles used to treat invasive agents |
US8968171B2 (en) | 2011-01-24 | 2015-03-03 | Endomagnetics Limited | System for correlating energy field characteristics with target particle characteristics in the application of an energy field to a living organism for imaging and treatment of invasive agents |
US20120190979A1 (en) | 2011-01-24 | 2012-07-26 | Actium BioSystems, LLC | System for automatically amending energy field characteristics in the application of an energy field to a living organism for treatment of invasive agents |
US9180307B2 (en) | 2011-03-15 | 2015-11-10 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method of reducing the occurrence of arrhythmias via photobiomodulation and apparatus for same |
US9095414B2 (en) * | 2011-06-24 | 2015-08-04 | The Regents Of The University Of California | Nonlinear optical photodynamic therapy (NLO-PDT) of the cornea |
EP2729175B1 (en) * | 2011-07-08 | 2021-12-01 | Duke University | System for light stimulation within a medium |
EP2747838B8 (en) | 2011-08-26 | 2019-07-17 | Endomagnetics Limited | Apparatus for the generation of an energy field for the treatment of cancer in body cavities and parts that are cavity-like |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US9267889B1 (en) * | 2011-10-12 | 2016-02-23 | Stc.Unm | High efficiency light absorbing and light emitting nanostructures |
WO2013086293A1 (en) * | 2011-12-08 | 2013-06-13 | Washington University | In vivo label-free histology by photoacoustic microscopy of cell nuclei |
CA2859364C (en) | 2011-12-16 | 2019-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
JP6537826B2 (ja) | 2012-02-21 | 2019-07-03 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 骨盤底の神経性障害を処置するための組成物および方法 |
WO2013151772A1 (en) * | 2012-04-06 | 2013-10-10 | The Regents Of The University Of California | Geometry enhancement of nanoscale energy deposition by x-rays |
US10322194B2 (en) | 2012-08-31 | 2019-06-18 | Sloan-Kettering Institute For Cancer Research | Particles, methods and uses thereof |
US9410007B2 (en) | 2012-09-27 | 2016-08-09 | Rhodia Operations | Process for making silver nanostructures and copolymer useful in such process |
KR102154207B1 (ko) | 2012-10-11 | 2020-09-10 | 나노콤포식스, 인크. | 은 나노플레이트 조성물 및 방법 |
WO2014107215A2 (en) * | 2012-10-16 | 2014-07-10 | Nanoptics, Incorporated | Method and apparatus for neutron detection utilizing pulse height discrimination and pulse shape discrimination |
CN105073142B (zh) | 2012-12-19 | 2019-12-10 | 索隆-基特林癌症研究协会 | 多模态粒子、其方法和用途 |
US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
EP2958481A4 (en) | 2013-02-20 | 2017-03-08 | Sloan-Kettering Institute for Cancer Research | Wide field raman imaging apparatus and associated methods |
US20140350534A1 (en) * | 2013-02-20 | 2014-11-27 | Sloan-Kettering Institute For Cancer Research | Raman based ablation/resection systems and methods |
US9261469B2 (en) * | 2013-03-07 | 2016-02-16 | Farida A. Selim | Luminescence based spectrometers |
US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
EP3690958A1 (en) * | 2013-03-15 | 2020-08-05 | Edward J. Britt | Energy conversion device |
ES2742492T3 (es) | 2013-03-15 | 2020-02-14 | Univ Leland Stanford Junior | Control optogenético del estado conductual |
WO2014179331A2 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
JP2014239871A (ja) * | 2013-05-07 | 2014-12-25 | 安東 秀夫 | 生体活動検出方法、生体活動測定装置、生体活動検出信号の転送方法および生体活動情報を利用したサービスの提供方法 |
KR20160068701A (ko) * | 2013-06-05 | 2016-06-15 | 하페치 파하드 | 유효성분을 광활성화시키는 것을 포함하는 조성물을 도포하는 방법 및 투여 방식을 가진 약제학적 조성물 |
CA2921221A1 (en) | 2013-08-14 | 2015-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
US9588327B2 (en) * | 2013-12-12 | 2017-03-07 | The Board Of Trustees Of The University Of Illinois | Nanoindenter multimodal microscope objective for mechanobiology |
US10912947B2 (en) | 2014-03-04 | 2021-02-09 | Memorial Sloan Kettering Cancer Center | Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells |
US20150265397A1 (en) * | 2014-03-21 | 2015-09-24 | Carl Zeiss Meditec Ag | Method for transplanting a part of the cornea and a surgical microscope therefor |
WO2015164487A1 (en) * | 2014-04-22 | 2015-10-29 | Immunolight, Llc | Interior energy-activation of photo-reactive species inside a medium or body using an x-ray source emitting low energy x-rays as initiation energy source |
GB2525432A (en) * | 2014-04-24 | 2015-10-28 | Univ Oslo Hf | Modification of extracorporeal photopheresis technology with porphyrin precursors |
WO2016018896A1 (en) | 2014-07-28 | 2016-02-04 | Memorial Sloan Kettering Cancer Center | Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes |
EP3183037B1 (en) * | 2014-08-18 | 2022-03-16 | Immunolight, Llc. | Compositions for selective activation of photoreactive responses |
US11007207B2 (en) * | 2014-08-29 | 2021-05-18 | University Of South Carolina | Preparations of gold/mesoporous silica hybrid nanoparticle and applications |
CN115350402A (zh) | 2014-09-09 | 2022-11-18 | 卢米希拉公司 | 用于非侵入性治疗的多波长光疗装置、系统和方法 |
CA2973200C (en) * | 2015-01-14 | 2023-09-26 | Immunolight, Llc | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs |
WO2016133959A1 (en) | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
EP3258938B1 (en) | 2015-02-17 | 2020-12-02 | Arizona Board of Regents on behalf of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
EP3317035A1 (en) | 2015-07-01 | 2018-05-09 | Memorial Sloan Kettering Cancer Center | Anisotropic particles, methods and uses thereof |
US11642547B2 (en) * | 2015-07-08 | 2023-05-09 | Wave Force Electronics Inc. | Bioresonance frequency emitting device, system, and method |
JP6965252B2 (ja) | 2015-10-19 | 2021-11-10 | イミュノライト・エルエルシー | X線ソラレン活性化がん治療(x−pact) |
FR3042874A1 (fr) * | 2015-10-21 | 2017-04-28 | Nanobacterie | Particule comprenant au moins une particule d'oxyde de fer ferrimagnetique associee a au moins un compose pour une utilisation medicale ou cosmetique |
US20190022220A1 (en) * | 2016-01-30 | 2019-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated anchoring of therapeutic factors to tissues |
WO2017180054A1 (en) * | 2016-04-14 | 2017-10-19 | Feldreich Gustav Nicolas | An apparatus for use in irradiation therapy comprising ionization module and uv-light source |
KR102465104B1 (ko) * | 2016-04-25 | 2022-11-10 | 이뮤노라이트, 엘엘씨 | 삽입 디바이스들 및 매질 내부에 방출 광의 생산을 위한 시스템들 및 이들의 사용 방법들 |
CN105942978A (zh) * | 2016-05-20 | 2016-09-21 | 北京普康大健康管理服务中心 | 一种schl量子生物能量全息检测仪和检测方法 |
CN105919592A (zh) * | 2016-05-20 | 2016-09-07 | 北京普康大健康管理服务中心 | 一种schl量子生物能量全息分析系统和分析方法 |
WO2017218537A1 (en) * | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting |
EP3495021B1 (en) * | 2016-08-05 | 2021-09-29 | Nagasaki Method & Co., Ltd. | Head part photic stimulation device and program |
US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
US11844605B2 (en) | 2016-11-10 | 2023-12-19 | The Research Foundation For Suny | System, method and biomarkers for airway obstruction |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
CN110167604B (zh) * | 2016-11-30 | 2022-02-08 | 瑞斯派特有限公司 | 用于将微生物破坏uv光从光源传送到目标的方法和装置 |
US20190381173A1 (en) * | 2017-01-27 | 2019-12-19 | Klox Technologies Inc. | Methods for photobiomodulation of biological processes using fluorescence generated and emitted from a biophotonic composition or a biophotonic system |
US20180229299A1 (en) * | 2017-02-15 | 2018-08-16 | The Board Of Trustees Of The University Of Arkansas | Copper-silica core-shell nanoparticles and methods |
US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
WO2019036444A1 (en) * | 2017-08-14 | 2019-02-21 | Veralase, LLC | MINIATURE PORTABLE LASER PROCESSING DEVICE |
WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
KR20190052241A (ko) * | 2017-11-08 | 2019-05-16 | 서울바이오시스 주식회사 | 의료용 캡슐 장치 |
US11484731B2 (en) | 2017-11-09 | 2022-11-01 | International Business Machines Corporation | Cognitive optogenetics probe and analysis |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
WO2019133997A1 (en) | 2017-12-31 | 2019-07-04 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
CN108508068B (zh) * | 2018-03-27 | 2020-07-24 | 长沙理工大学 | 阴离子卟啉-碳纳米管修饰电极测her2基因特定序列 |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
JP2021531087A (ja) * | 2018-07-13 | 2021-11-18 | バード・ペリフェラル・バスキュラー・インコーポレーテッド | 移植可能ポート、移植可能ポート検出装置、およびその方法 |
EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | SLEEP ENHANCEMENT SYSTEM AND METHOD |
CN113272011B (zh) * | 2018-10-12 | 2024-07-12 | 免疫之光有限责任公司 | 用于测量和诱发细胞间通信的方法、装置和组合物及其治疗性用途 |
US10463874B1 (en) * | 2019-01-15 | 2019-11-05 | Nadia Ansari | Systems and methods for providing cold laser therapy to a patient in a hands-free manner |
US20220184211A1 (en) * | 2019-03-04 | 2022-06-16 | Immunolight, Llc | Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in methods and systems for treating cell proliferation disorders |
SE2000055A1 (sv) * | 2020-03-15 | 2021-09-16 | Martin Ivanov Denev | Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler |
EP4146073A4 (en) * | 2020-05-05 | 2024-06-12 | Lumeda Inc. | TIME DIVISION DOSIMETRY SYSTEM AND METHOD |
TWI764421B (zh) * | 2020-12-09 | 2022-05-11 | 羅莎國際有限公司 | 高分子低溫離子氣體促進傷口癒合裝置 |
RU2754617C1 (ru) * | 2021-01-11 | 2021-09-06 | Общество С Ограниченной Ответственностью "Лаборатория Инновационных Технологий" | Способ получения фармацевтического средства для торможения пролиферативной активности опухолевых клеток |
CN112843089B (zh) * | 2021-01-29 | 2021-10-29 | 燕山大学 | 一种改善肿瘤微环境的钌基抗肿瘤纳米药物的制备方法 |
KR102355947B1 (ko) * | 2021-03-23 | 2022-02-08 | 어썸레이 주식회사 | 전자기파를 이용한 염증성 질환의 치료, 억제 및 예방을 위한 치료 장치 및 방법 |
CN113563876B (zh) * | 2021-07-06 | 2022-09-27 | 江南大学 | 一种增强型黄光碳点及其制备方法和应用 |
WO2024026041A1 (en) * | 2022-07-29 | 2024-02-01 | Board Of Trustees Of Michigan State University | Remote control and quantitative monitoring of drug release from nanoparticles based on magnetic particle imaging |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111890A (en) * | 1977-12-19 | 1978-09-05 | Sws Silicones Corporation | Curable organopolysiloxane compositions containing titanium esters |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4748120A (en) | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4675346A (en) * | 1983-06-20 | 1987-06-23 | Loctite Corporation | UV curable silicone rubber compositions |
US4705952A (en) | 1985-10-10 | 1987-11-10 | Quantex Corporation | Communications apparatus using infrared-triggered phosphor for receiving infrared signals |
US4838852A (en) | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
US5091385A (en) * | 1988-09-30 | 1992-02-25 | Baylor Research Institute | Pre-activated therapeutic agents derived from photoactive compounds |
US5177073A (en) * | 1988-09-30 | 1993-01-05 | Baylor Research Institute | Therapeutic compositions derived from photoactive compounds |
US5216176A (en) | 1989-01-23 | 1993-06-01 | Lehigh University | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor |
US4979935A (en) | 1989-02-21 | 1990-12-25 | Quantex Corporation | Method of photodynamic therapy employing electron trapping material |
US5658722A (en) * | 1990-05-15 | 1997-08-19 | New York Blood Center, Inc. | Process for the sterilization of biological compositions using UVA1 irradiation |
US5120649A (en) * | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
US5118422A (en) * | 1990-07-24 | 1992-06-02 | Photo-Catalytics, Inc. | Photocatalytic treatment of water |
WO1993000005A1 (en) * | 1991-06-21 | 1993-01-07 | Baxter International Inc. | Method for inactivating pathogens in a body fluid |
US6204058B1 (en) | 1992-02-07 | 2001-03-20 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6669965B2 (en) | 1992-02-07 | 2003-12-30 | Vasogen Ireland Limited | Method of treating atherosclerosis |
US5980954A (en) | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US5257970A (en) | 1992-04-09 | 1993-11-02 | Health Research, Inc. | In situ photodynamic therapy |
US5807881A (en) | 1992-05-27 | 1998-09-15 | Quadra Logic Technologies, Inc. | Method for selectively reducing activated leukocyte cell population |
WO1994014956A1 (en) * | 1992-12-23 | 1994-07-07 | Iowa State University Research Foundation, Inc. | Molecular flashlight |
US5728590A (en) * | 1994-07-29 | 1998-03-17 | Nanoprobes, Inc. | Small organometallic probes |
US5521289A (en) * | 1994-07-29 | 1996-05-28 | Nanoprobes, Inc. | Small organometallic probes |
US6121425A (en) * | 1994-07-29 | 2000-09-19 | Nanoprobes, Inc. | Metal-lipid molecules |
JPH0867682A (ja) * | 1994-08-30 | 1996-03-12 | Toyo Hatsuka Kogyo Kk | ニトロイミダゾール担持ポルフィリン誘導体とその用 途 |
US6235508B1 (en) | 1995-06-07 | 2001-05-22 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
IT1275571B (it) * | 1995-07-19 | 1997-08-07 | Consiglio Nazionale Ricerche | Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori |
JP3689939B2 (ja) | 1995-07-28 | 2005-08-31 | 豊田合成株式会社 | 光触媒装置 |
AU7237896A (en) | 1995-09-06 | 1997-03-27 | Research Foundation Of The State University Of New York, The | Two-photon upconverting dyes and applications |
IL126366A (en) | 1996-03-29 | 2011-10-31 | Therakos Inc | Use of a photoactivatable compound in the manufacture of a medicament for the treatment of an infection |
JPH09299937A (ja) | 1996-05-09 | 1997-11-25 | Daikin Ind Ltd | 被処理体処理装置 |
JPH1010741A (ja) * | 1996-06-27 | 1998-01-16 | Dow Corning Asia Kk | 紫外線硬化性ポリシロキサン組成物およびこれを用いた硬化物パターンの製造方法 |
WO1998004318A1 (en) * | 1996-07-25 | 1998-02-05 | Light Medicine, Inc. | Photodynamic therapy with light emitting particles in bloodstream |
US5829448A (en) | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
US6344272B1 (en) * | 1997-03-12 | 2002-02-05 | Wm. Marsh Rice University | Metal nanoshells |
US5957960A (en) | 1997-05-05 | 1999-09-28 | Light Sciences Limited Partnership | Internal two photon excitation device for delivery of PDT to diffuse abnormal cells |
US6071944A (en) * | 1997-11-12 | 2000-06-06 | Bowling Green State University | Method of treatment of pigmented cancer cells utilizing photodynamic therapy |
US7267948B2 (en) * | 1997-11-26 | 2007-09-11 | Ut-Battelle, Llc | SERS diagnostic platforms, methods and systems microarrays, biosensors and biochips |
US20030022170A1 (en) * | 1998-03-06 | 2003-01-30 | Millenium Pharmaceuticals, Inc. | Novel fibroblast growth factors and therapeutic and diagnostic uses therefor |
US6323253B1 (en) * | 1998-06-01 | 2001-11-27 | Loctite Corporation | Flame-retardant UV and UV/moisture curable silicone compositions |
AU4215299A (en) * | 1998-06-01 | 1999-12-20 | Loctite Corporation | Flame-retardant uv curable silicone compositions |
WO2000006244A2 (en) * | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US7045124B1 (en) | 1999-01-12 | 2006-05-16 | Vasogen Irelend Limited | Pre-conditioning against cell death |
US6609014B1 (en) | 1999-04-14 | 2003-08-19 | Qlt Inc. | Use of PDT to inhibit intimal hyperplasia |
WO2001005001A1 (en) | 1999-07-12 | 2001-01-18 | Massachusetts Institute Of Technology | Resonant microcavities |
US6719778B1 (en) * | 2000-03-24 | 2004-04-13 | Endovascular Technologies, Inc. | Methods for treatment of aneurysms |
WO2001082297A1 (en) | 2000-04-20 | 2001-11-01 | Koninklijke Philips Electronics N.V. | Optical recording medium and use of such optical recording medium |
US6811562B1 (en) | 2000-07-31 | 2004-11-02 | Epicor, Inc. | Procedures for photodynamic cardiac ablation therapy and devices for those procedures |
US6589948B1 (en) | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
US20060020309A1 (en) * | 2004-04-09 | 2006-01-26 | Palomar Medical Technologies, Inc. | Methods and products for producing lattices of EMR-treated islets in tissues, and uses therefor |
US20020127224A1 (en) * | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
US7364872B1 (en) * | 2001-03-30 | 2008-04-29 | Nanoprobes | Test methods using enzymatic deposition and alteration of metals |
US6670113B2 (en) * | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
EP1404334A4 (en) * | 2001-05-15 | 2005-02-02 | Faulk Pharmaceuticals Inc | TARGETED ADMINISTRATION OF BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER |
WO2002096366A2 (en) | 2001-05-31 | 2002-12-05 | Miravant Pharmaceuticals, Inc. | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
US7008559B2 (en) | 2001-06-06 | 2006-03-07 | Nomadics, Inc. | Manganese doped upconversion luminescence nanoparticles |
GB0118251D0 (en) * | 2001-07-26 | 2001-09-19 | Photocure Asa | Method |
US7303578B2 (en) | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
AU2002332697A1 (en) | 2001-12-12 | 2003-06-23 | Leon J. Lewandowski | Photophoretic auto immune stimulation |
US20070189359A1 (en) * | 2002-06-12 | 2007-08-16 | Wei Chen | Nanoparticle thermometry and pressure sensors |
US6908591B2 (en) | 2002-07-18 | 2005-06-21 | Clearant, Inc. | Methods for sterilizing biological materials by irradiation over a temperature gradient |
US20040253138A1 (en) * | 2003-06-16 | 2004-12-16 | American Environmental Systems, Inc. | Plasmon enhanced body treatment and bacterial management |
CN1874789A (zh) * | 2003-09-23 | 2006-12-06 | 光科学公司 | 用于光动力疗法的缀合物 |
JP2007514736A (ja) * | 2003-12-17 | 2007-06-07 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 紫外線放射ナノ粒子を用いた放射線治療および医学画像 |
US7294656B2 (en) * | 2004-01-09 | 2007-11-13 | Bayer Materialscience Llc | UV curable coating composition |
FR2869803B1 (fr) * | 2004-05-10 | 2006-07-28 | Nanobiotix Sarl | Particules activables, preparation et utilisations |
US7274772B2 (en) * | 2004-05-27 | 2007-09-25 | Cabot Microelectronics Corporation | X-ray source with nonparallel geometry |
JP2005349028A (ja) * | 2004-06-11 | 2005-12-22 | Shibuya Kogyo Co Ltd | 腫瘍治療方法及びその装置 |
GB0415263D0 (en) | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
GB0415663D0 (en) * | 2004-07-13 | 2004-08-18 | Psimei Pharmaceuticals Plc | Compound |
GB2416699B (en) * | 2004-08-05 | 2010-04-14 | Photo Therapeutics Ltd | Skin rejuvenation |
US20060067889A1 (en) * | 2004-09-27 | 2006-03-30 | Light Sciences Corporation | Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents |
WO2006037081A2 (en) * | 2004-09-28 | 2006-04-06 | The Regents Of The University Of California | Nanoparticle radiosensitizers |
US20060089836A1 (en) * | 2004-10-21 | 2006-04-27 | Motorola, Inc. | System and method of signal pre-conditioning with adaptive spectral tilt compensation for audio equalization |
FR2877571B1 (fr) * | 2004-11-05 | 2007-04-13 | Nanobiotix Sarl | Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations |
US20060115495A1 (en) * | 2004-11-12 | 2006-06-01 | Board Of Regents, The University Of Texas System | Protein-noble metal nanoparticles |
US7999161B2 (en) * | 2005-01-22 | 2011-08-16 | Alexander Oraevsky | Laser-activated nanothermolysis of cells |
US7397043B2 (en) * | 2005-01-26 | 2008-07-08 | Nomadics, Inc. | Standoff optical detection platform based on surface plasmon-coupled emission |
US20070218049A1 (en) * | 2006-02-02 | 2007-09-20 | Wei Chen | Nanoparticle based photodynamic therapy and methods of making and using same |
US7538329B2 (en) * | 2005-02-02 | 2009-05-26 | Nomadics, Inc. | Energy-transfer nanocomposite materials and methods of making and using same |
JP2006290840A (ja) | 2005-04-14 | 2006-10-26 | Shetech:Kk | 白金ナノ粒子を含有する活性酸素種除去材 |
IL168184A (en) * | 2005-04-21 | 2011-11-30 | Univ Ariel Res & Dev Co Ltd | Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy |
US9588124B2 (en) * | 2005-05-11 | 2017-03-07 | Georgia Tech Research Corporation | Shape tunable plasmonic nanoparticles |
WO2007023398A2 (en) * | 2005-05-16 | 2007-03-01 | Universite De Geneve | Compounds for photochemotherapy |
JP4751691B2 (ja) * | 2005-10-12 | 2011-08-17 | トヨタ自動車株式会社 | 核酸高分子の分解方法及び分解装置 |
EP1779891A1 (en) | 2005-10-28 | 2007-05-02 | Abdula Kurkayev | Method of activating a photosensitizer |
EP1998684A4 (en) * | 2006-03-10 | 2014-09-17 | Massachusetts Inst Technology | CONJUGATES AND NANOSYSTEMS WITH TRIGGERED SELF ASSEMBLY |
US20100240530A1 (en) | 2006-03-22 | 2010-09-23 | Kiichirou Sumi | Method for producing metallic coating material for catalyst, and metallic coating material for catalyst |
US20070243137A1 (en) * | 2006-04-18 | 2007-10-18 | Nanoprobes, Inc. | Cell and sub-cell methods for imaging and therapy |
WO2008007290A2 (en) | 2006-07-10 | 2008-01-17 | Philips Intellectual Property & Standards Gmbh | Core-shell nanoparticles for thearapy and imaging purposes |
GB0712287D0 (en) * | 2007-06-22 | 2007-08-01 | Ucl Business Plc | Antimicrobial Conjugates |
US8328785B2 (en) * | 2006-09-18 | 2012-12-11 | The University Of Houston System | Use of nanoparticles in the photodynamic treatment of tumors |
US7906147B2 (en) * | 2006-10-12 | 2011-03-15 | Nanoprobes, Inc. | Functional associative coatings for nanoparticles |
JP2008137939A (ja) * | 2006-12-01 | 2008-06-19 | National Institute Of Advanced Industrial & Technology | X線治療用助剤 |
US9358292B2 (en) * | 2007-04-08 | 2016-06-07 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders |
CN101101263A (zh) * | 2007-07-20 | 2008-01-09 | 苏州大学 | 高活性表面增强拉曼光谱的核壳纳米粒子及其制备方法 |
US20090104212A1 (en) * | 2007-08-06 | 2009-04-23 | Immunolight | Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption |
US9439897B2 (en) * | 2007-11-06 | 2016-09-13 | Immunolight, Llc | Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders |
ITBS20070177A1 (it) | 2007-11-15 | 2009-05-16 | Paoli Ambrosi Gianfranco De | Composizione per uso topico per ottenere un rapido ed intenso effetto lifting |
TWI458512B (zh) * | 2008-02-21 | 2014-11-01 | Immunolight Llc | 利用電漿子增強之光譜療法(pepst)及激子-電漿增強之光療法〈epep〉治療細胞增生病症之組合物及產生自體疫苗之系統 |
CL2009000560A1 (es) * | 2008-03-11 | 2010-02-19 | Univ Duke | Un metodo para endurecer un medio endurecible por radiacion que comprende colocar una composicion dentro de un objeto para ser endurecido, la aplicacion de al menos uno elegido entre rayos x, rayos gama o haz de electrones a traves del objeto y dentro de la composicion. |
US8770203B2 (en) * | 2008-07-14 | 2014-07-08 | Immunolight, Llc. | Advanced methods and systems for treating cell proliferation disorders |
-
2009
- 2009-04-02 CN CN201510641152.4A patent/CN105288619A/zh active Pending
- 2009-04-02 CA CA2720513A patent/CA2720513C/en active Active
- 2009-04-02 CA CA3095369A patent/CA3095369C/en active Active
- 2009-04-02 EP EP17197468.6A patent/EP3300744A1/en not_active Ceased
- 2009-04-02 CN CN200980121111.5A patent/CN102056625B/zh active Active
- 2009-04-02 CA CA2906990A patent/CA2906990A1/en not_active Abandoned
- 2009-04-02 CN CN202110427393.4A patent/CN113274496A/zh active Pending
- 2009-04-02 WO PCT/US2009/039300 patent/WO2009124189A1/en active Application Filing
- 2009-04-02 EP EP09726873.4A patent/EP2268311A4/en not_active Withdrawn
- 2009-04-02 JP JP2011503172A patent/JP5967935B2/ja active Active
- 2009-04-03 TW TW104121004A patent/TWI615170B/zh active
- 2009-04-03 AR ARP090101189A patent/AR071831A1/es unknown
- 2009-04-03 US US12/417,779 patent/US20100016783A1/en not_active Abandoned
- 2009-04-03 TW TW098111303A patent/TWI500433B/zh active
- 2009-04-03 TW TW106139211A patent/TWI741064B/zh active
- 2009-04-03 CL CL2009000816A patent/CL2009000816A1/es unknown
- 2009-04-04 SA SA109300207A patent/SA109300207B1/ar unknown
-
2014
- 2014-11-14 JP JP2014231745A patent/JP6000319B2/ja active Active
-
2016
- 2016-04-04 JP JP2016075090A patent/JP6174185B2/ja active Active
- 2016-05-11 US US15/151,642 patent/US10391330B2/en active Active
- 2016-06-07 JP JP2016113368A patent/JP2016166244A/ja active Pending
-
2017
- 2017-12-07 JP JP2017235146A patent/JP2018043996A/ja active Pending
-
2019
- 2019-07-15 US US16/511,605 patent/US20190336786A1/en not_active Abandoned
-
2022
- 2022-09-09 US US17/931,105 patent/US20230029054A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071831A1 (es) | Sistemas no invasivos y metodos para fotobiomodulacion in situ. composicion farmaceutica. kit. | |
BRPI0513278A (pt) | uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton | |
CO6270362A2 (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
AR070461A1 (es) | Metodos y sistemas para tratar trastornos de proliferacion celular usando terapia fotoespectral mejorada con plasmonicos (pepst) y fototerapia mejorada con excitones plasmones (epep). composiciones. | |
UY31800A (es) | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb | |
CL2009001476A1 (es) | Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular. | |
CR20170477A (es) | Terapia de combinacin del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cncer | |
AR087754A1 (es) | 6h-tieno[3,2,-f][1,2,4]triazolo[4,3-a][1,4]diazepina | |
PA8828201A1 (es) | Compuestos triazina como inhibidores mtor y quinasa p13 | |
MX2009004060A (es) | Moduladores de proteina cinasa de triazolpiridazina. | |
GT201000082A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
HN2011000193A (es) | Derivados de piridazina como inhibidores de smo | |
GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
CO6382129A2 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes | |
UY31830A (es) | Activadores de glucoquinasa | |
CL2004000720A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR | |
AR066899A1 (es) | Metodos y disposiciones para el tratamiento de trastornos de proliferacion celular | |
PE20070621A1 (es) | 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas | |
AR067794A1 (es) | Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros y el metodo de preparacion del compuesto | |
ECSP055575A (es) | Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
GT200500228A (es) | Prodroga de benzoxazoles sustituidos como agentes estrogenicos | |
GT200700103A (es) | Compuestos biciclocarboxiamida sustituidos | |
UY32010A (es) | Nuevas indolinonas, composiciones conteniéndolas y aplicaciones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |